Israel Englander Arcus Biosciences, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 780,088 shares of RCUS stock, worth $7.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

780,088

Previous 1,194,622 34.7%

Holding current value

$7.54 Million

Previous $9.38 Million 32.29%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.87 - $10.03 $2.85 Million - $4.16 Million	-414,534 Reduced 34.7%	780,088 $6.35 Million
Q1 2025 May 15, 2025	BUY	$7.85 - $15.24 $2.12 Million - $4.12 Million	270,253 Added 29.24%	1,194,622 $9.38 Million
Q4 2024 Feb 14, 2025	BUY	$14.28 - $18.44 $9.7 Million - $12.5 Million	679,267 Added 277.14%	924,369 $13.8 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $950,044 - $1.25 Million	69,397 Added 39.5%	245,102 $3.75 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $2.56 Million - $3.25 Million	175,705 New	175,705 $2.68 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $321,661 - $470,158	-23,951 Reduced 43.28%	31,394 $599,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $939,204 - $1.22 Million	55,345 New	55,345 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $2.6 Million - $4.72 Million	132,066 Added 1051.4%	144,627 $2.99 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $2.58 Million - $3.34 Million	-111,199 Reduced 89.85%	12,561 $329,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $1.69 Million - $3.71 Million	98,303 Added 386.15%	123,760 $3.14 Million
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $1.4 Million - $2.03 Million	-48,438 Reduced 65.55%	25,457 $803,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $1.95 Million - $3.01 Million	62,151 Added 529.21%	73,895 $2.99 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $4.34 Million - $6.07 Million	-160,988 Reduced 93.2%	11,744 $410,000
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $3.3 Million - $5.19 Million	144,969 Added 522.17%	172,732 $4.74 Million
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $284,908 - $450,778	10,891 Added 64.55%	27,763 $780,000
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $4.86 Million - $9.26 Million	-286,157 Reduced 94.43%	16,872 $438,000
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $2.85 Million - $4.24 Million	-166,378 Reduced 35.44%	303,029 $5.19 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $219,594 - $574,686	15,719 Added 3.46%	469,407 $11.6 Million
Q1 2020 May 14, 2020	BUY	$8.78 - $19.28 $2.66 Million - $5.84 Million	302,739 Added 200.56%	453,688 $6.3 Million
Q4 2019 Feb 14, 2020	SELL	$7.33 - $10.79 $275,241 - $405,164	-37,550 Reduced 19.92%	150,949 $1.53 Million
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $713,313 - $1.13 Million	110,763 Added 142.49%	188,499 $1.72 Million
Q2 2019 Aug 15, 2019	SELL	$7.29 - $13.38 $738,440 - $1.36 Million	-101,295 Reduced 56.58%	77,736 $618,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $1.31 Million - $2.4 Million	179,031 New	179,031 $15.7 Million
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $1.37 Million - $2.05 Million	-141,077 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.95 $1.24 Million - $1.7 Million	113,654 Added 414.45%	141,077 $1.97 Million
Q2 2018 Aug 14, 2018	SELL	$12.24 - $17.05 $2.19 Million - $3.04 Million	-178,518 Reduced 86.68%	27,423 $336,000
Q1 2018 May 15, 2018	BUY	$15.44 - $17.71 $3.18 Million - $3.65 Million	205,941 New	205,941 $3.18 Million

Others Institutions Holding RCUS

# of Institutions

206

Shares Held

67M

Call Options Held

3.18M

Put Options Held

167K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $698M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account